Childhood Acute Lymphoblastic Leukemia

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy.

Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail.

This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

Exhaustively reviews current therapeutic strategies and applications of precision medicine in ALL treatment Provides scientists and clinicians with state of the art knowledge to guide their research and clinical management Written by an international multidisciplinary team of authors

Autorentext

Professor Ajay Vora is honorary professor of paediatric haematology at University of Sheffield and consultant paediatric haematologist at Sheffield Children's Hospital. His daily practice involves the care of children with a variety of malignant and non-malignant blood disorders. He has a special interest in childhood leukaemia and cord blood transplantation. He is chair of the UK NCRI childhood leukaemia sub-group and I-BFM ALL committee. He is chief investigator of childhood and infant ALL clinical trials and is involved with several research projects in this area. He is programme director of the Trent Regional Paediatric Haemopoeitic Stem Cell transplant service.

Inhalt
Epidemiology including genetic predisposition.- Clinical Features.- Diagnostic flow cytometry and immunophenotypic classification.- Cytogenetics.- Molecular genetics.- Pharmacology including pharmacokinetics, pharmacodynamics and pharmacogenetics.- Minimal Residual Disease.- Treatment first line.- Treatment relapse.- Treatment new drugs.- Treatment immune based approaches. Cellular therapy.- Supportive care.- Developing world perspective.